# CTMX — CytomX Therapeutics Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** CTMX  
**Sources:** 16  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-ctmx-cytomx-therapeutics-inc-catalysts-narrative-risks-10565

---

# CytomX Therapeutics, Inc. (Nasdaq: CTMX) — Point-in-Time Research (as of 2026-11-01)

**Company profile:** CytomX is a clinical-stage, oncology-focused biopharmaceutical company based in South San Francisco, operating on its masked, conditionally activated PROBODY® platform, with a pipeline that includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801 [[2]](https://markets.businessinsider.com/news/stocks/cytomx-therapeutics-to-report-third-quarter-2026-financial-results-on-november-5-2026-1036684678). As of the latest data the stock traded around USD 2.24–2.34, with a market capitalization near USD 500–522 million [[5]](https://www.ad-hoc-news.de/boerse/news/nebenwerte/cytomx-therapeutics-stock-trades-ahead-of-november-5-results/70331503)[[10]](https://tickernerd.com/stock/ctmx-forecast/)[[11]](https://stockanalysis.com/stocks/ctmx/forecast/)[[18]](https://askthedate.com/America/New_York/en/earnings-calendar/2026-11-05/CTMX/).

## Key recent catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-ctmx-cytomx-therapeutics-inc-catalysts-narrative-risks-10565 (free to sign up)._